Validation of an improved scale for rating L-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists

Irene Sebastianutto, Natallia Maslava, Corey R Hopkins, M. Angela Cenci

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Rodent models of L-DOPA-induced dyskinesia (LID) are essential to investigate pathophysiological mechanisms and treatment options. Ratings of abnormal involuntary movements (AIMs) are used to capture both qualitative and quantitative features of dyskinetic behaviors. Thus far, validated rating scales for the mouse have anchored the definition of severity to the time during which AIMs are present. Here we have asked whether the severity of axial, limb, and orolingual AIMs can be objectively assessed with scores based on movement amplitude. Mice sustained 6-OHDA lesions in the medial forebrain bundle and were treated with L-DOPA (3–6 mg/kg/day) until they developed stable AIMs scores. Two independent investigators rated AIM severity using both the validated time-based scale and a novel amplitude scale, evaluating the degree of deviation of dyskinetic body parts relative to their resting position. The amplitude scale yielded a high degree of consistency both within- and between raters. Thus, time-based scores, amplitude scores, and a combination of the two (‘global AIM scores’) were applied to compare antidyskinetic effects produced by amantadine and by the following subtype-specific DA receptor antagonists: SCH23390 (D1/D5), Raclopride (D2/D3), PG01037 (D3), L-745,870 (D4), and VU6004461 (D4). SCH23390 and Raclopride produced similarly robust reductions in both time-based scores and amplitude scores, while PG01037 and L-745,870 had more partial effects. Interestingly, a novel and highly brain penetrable D4 receptor antagonist (VU6004461) markedly attenuated both time-based and amplitude scores without diminishing the general motor stimulant effect of L-DOPA. In summary, our results show that a dyskinesia scale combining a time dimension with an amplitude dimension (‘global AIMs’) is more sensitive than unidimensional scales. Moreover, the antidyskinetic effects produced by two chemically distinct D4 antagonists identify the D4 receptor as a potential future target for the treatment of LID.

Original languageEnglish (US)
Pages (from-to)156-170
Number of pages15
JournalNeurobiology of Disease
Volume96
DOIs
StatePublished - Dec 1 2016

Fingerprint

Dopamine Antagonists
Dyskinesias
3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine
Raclopride
Medial Forebrain Bundle
Amantadine
Oxidopamine

Keywords

  • Dystonia
  • Experimental therapeutics
  • Movement disorders
  • Parkinson's disease
  • Rodent models

ASJC Scopus subject areas

  • Neurology

Cite this

Validation of an improved scale for rating L-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists. / Sebastianutto, Irene; Maslava, Natallia; Hopkins, Corey R; Cenci, M. Angela.

In: Neurobiology of Disease, Vol. 96, 01.12.2016, p. 156-170.

Research output: Contribution to journalArticle

@article{63b0b214ea87409ea7653aec46dcffd4,
title = "Validation of an improved scale for rating L-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists",
abstract = "Rodent models of L-DOPA-induced dyskinesia (LID) are essential to investigate pathophysiological mechanisms and treatment options. Ratings of abnormal involuntary movements (AIMs) are used to capture both qualitative and quantitative features of dyskinetic behaviors. Thus far, validated rating scales for the mouse have anchored the definition of severity to the time during which AIMs are present. Here we have asked whether the severity of axial, limb, and orolingual AIMs can be objectively assessed with scores based on movement amplitude. Mice sustained 6-OHDA lesions in the medial forebrain bundle and were treated with L-DOPA (3–6 mg/kg/day) until they developed stable AIMs scores. Two independent investigators rated AIM severity using both the validated time-based scale and a novel amplitude scale, evaluating the degree of deviation of dyskinetic body parts relative to their resting position. The amplitude scale yielded a high degree of consistency both within- and between raters. Thus, time-based scores, amplitude scores, and a combination of the two (‘global AIM scores’) were applied to compare antidyskinetic effects produced by amantadine and by the following subtype-specific DA receptor antagonists: SCH23390 (D1/D5), Raclopride (D2/D3), PG01037 (D3), L-745,870 (D4), and VU6004461 (D4). SCH23390 and Raclopride produced similarly robust reductions in both time-based scores and amplitude scores, while PG01037 and L-745,870 had more partial effects. Interestingly, a novel and highly brain penetrable D4 receptor antagonist (VU6004461) markedly attenuated both time-based and amplitude scores without diminishing the general motor stimulant effect of L-DOPA. In summary, our results show that a dyskinesia scale combining a time dimension with an amplitude dimension (‘global AIMs’) is more sensitive than unidimensional scales. Moreover, the antidyskinetic effects produced by two chemically distinct D4 antagonists identify the D4 receptor as a potential future target for the treatment of LID.",
keywords = "Dystonia, Experimental therapeutics, Movement disorders, Parkinson's disease, Rodent models",
author = "Irene Sebastianutto and Natallia Maslava and Hopkins, {Corey R} and Cenci, {M. Angela}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.nbd.2016.09.001",
language = "English (US)",
volume = "96",
pages = "156--170",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Validation of an improved scale for rating L-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists

AU - Sebastianutto, Irene

AU - Maslava, Natallia

AU - Hopkins, Corey R

AU - Cenci, M. Angela

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Rodent models of L-DOPA-induced dyskinesia (LID) are essential to investigate pathophysiological mechanisms and treatment options. Ratings of abnormal involuntary movements (AIMs) are used to capture both qualitative and quantitative features of dyskinetic behaviors. Thus far, validated rating scales for the mouse have anchored the definition of severity to the time during which AIMs are present. Here we have asked whether the severity of axial, limb, and orolingual AIMs can be objectively assessed with scores based on movement amplitude. Mice sustained 6-OHDA lesions in the medial forebrain bundle and were treated with L-DOPA (3–6 mg/kg/day) until they developed stable AIMs scores. Two independent investigators rated AIM severity using both the validated time-based scale and a novel amplitude scale, evaluating the degree of deviation of dyskinetic body parts relative to their resting position. The amplitude scale yielded a high degree of consistency both within- and between raters. Thus, time-based scores, amplitude scores, and a combination of the two (‘global AIM scores’) were applied to compare antidyskinetic effects produced by amantadine and by the following subtype-specific DA receptor antagonists: SCH23390 (D1/D5), Raclopride (D2/D3), PG01037 (D3), L-745,870 (D4), and VU6004461 (D4). SCH23390 and Raclopride produced similarly robust reductions in both time-based scores and amplitude scores, while PG01037 and L-745,870 had more partial effects. Interestingly, a novel and highly brain penetrable D4 receptor antagonist (VU6004461) markedly attenuated both time-based and amplitude scores without diminishing the general motor stimulant effect of L-DOPA. In summary, our results show that a dyskinesia scale combining a time dimension with an amplitude dimension (‘global AIMs’) is more sensitive than unidimensional scales. Moreover, the antidyskinetic effects produced by two chemically distinct D4 antagonists identify the D4 receptor as a potential future target for the treatment of LID.

AB - Rodent models of L-DOPA-induced dyskinesia (LID) are essential to investigate pathophysiological mechanisms and treatment options. Ratings of abnormal involuntary movements (AIMs) are used to capture both qualitative and quantitative features of dyskinetic behaviors. Thus far, validated rating scales for the mouse have anchored the definition of severity to the time during which AIMs are present. Here we have asked whether the severity of axial, limb, and orolingual AIMs can be objectively assessed with scores based on movement amplitude. Mice sustained 6-OHDA lesions in the medial forebrain bundle and were treated with L-DOPA (3–6 mg/kg/day) until they developed stable AIMs scores. Two independent investigators rated AIM severity using both the validated time-based scale and a novel amplitude scale, evaluating the degree of deviation of dyskinetic body parts relative to their resting position. The amplitude scale yielded a high degree of consistency both within- and between raters. Thus, time-based scores, amplitude scores, and a combination of the two (‘global AIM scores’) were applied to compare antidyskinetic effects produced by amantadine and by the following subtype-specific DA receptor antagonists: SCH23390 (D1/D5), Raclopride (D2/D3), PG01037 (D3), L-745,870 (D4), and VU6004461 (D4). SCH23390 and Raclopride produced similarly robust reductions in both time-based scores and amplitude scores, while PG01037 and L-745,870 had more partial effects. Interestingly, a novel and highly brain penetrable D4 receptor antagonist (VU6004461) markedly attenuated both time-based and amplitude scores without diminishing the general motor stimulant effect of L-DOPA. In summary, our results show that a dyskinesia scale combining a time dimension with an amplitude dimension (‘global AIMs’) is more sensitive than unidimensional scales. Moreover, the antidyskinetic effects produced by two chemically distinct D4 antagonists identify the D4 receptor as a potential future target for the treatment of LID.

KW - Dystonia

KW - Experimental therapeutics

KW - Movement disorders

KW - Parkinson's disease

KW - Rodent models

UR - http://www.scopus.com/inward/record.url?scp=84987956578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987956578&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2016.09.001

DO - 10.1016/j.nbd.2016.09.001

M3 - Article

C2 - 27597526

AN - SCOPUS:84987956578

VL - 96

SP - 156

EP - 170

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -